AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 AUG 7 - (NewsRx.com & NewsRx.net) -- Buprenorphine use in opioid-dependent mothers is safe for neonates.
According to a study from the United States, "tt is estimated that 55-94% of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptoms of opioid withdrawal following abrupt termination in adults. To date, there have been 21 published reports representing approximately 15 evaluable cohorts of infants exposed to buprenorphine in utero."
"Of approximately 309 infants exposed, a neonatal abstinence syndrome (NAS) has been reported in 62% infants with 48% requiring treatment; apparently greater than 40% of these cases are confounded by illicit drug use," wrote R.E. Johnson and colleagues, Johns Hopkins University, School of Medicine.
"The NAS associated with buprenorphine generally appears within 12-48 hours, peaks at approximately 72-96 hours, and lasts for 120-168 hours. These results appear similar to or less than that observed following in utero ...
Source: HighBeam Research, Buprenorphine use in opioid-dependent mothers is safe for neonates.